Loading…
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $39M | $-303M | $-311M | $-234M | -19.7% | -16.7% | - |
| 2024 | $47M | $-216M | $-224M | $-207M | -26.8% | -40.1% | - |
| 2023 | $79M | $-143M | $-147M | $-137M | -37.2% | 67.8% | - |
| 2022 | $47M | $-152M | $-155M | $-156M | -31.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 46.83 | 78.59 | 47.07 | 39.21 |
| Operating Expense | 208.08 | 244.12 | 303.78 | 384.75 |
| Operating Income | -161.26 | -165.53 | -256.71 | -345.54 |
| EBITDA | -151.66 | -143.20 | -216.24 | -302.67 |
| EBIT | -154.63 | -146.77 | -223.61 | -310.98 |
| Pretax Income | -154.81 | -146.96 | -223.86 | -311.35 |
| Net Income | -154.81 | -146.96 | -223.86 | -311.35 |
| Net Income Common Stockholders | -154.81 | -146.96 | -223.86 | -311.35 |
| Total Expenses | 208.08 | 244.12 | 303.78 | 384.75 |
| Interest Expense | 0.18 | 0.20 | 0.25 | 0.37 |
| Interest Income | 6.62 | 18.76 | 38.03 | 38.42 |
| Research And Development | 164.25 | 189.08 | 240.25 | 316.57 |
| Selling General And Administration | 43.83 | 55.04 | 63.53 | 68.19 |
| Normalized EBITDA | -151.66 | -143.20 | -211.31 | -298.81 |
| Normalized Income | -154.81 | -146.96 | -218.93 | -307.50 |
| Basic EPS | -2.87 | -2.52 | -2.98 | 0 |
| Diluted EPS | -2.87 | -2.52 | -2.98 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | -4.92 | -3.85 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | -4.92 | -3.85 |
| Net Income From Continuing Operation Net Minority Interest | -154.81 | -146.96 | -223.86 | -311.35 |
| Reconciled Depreciation | 2.98 | 3.56 | 7.37 | 8.31 |
| Net Interest Income | 6.45 | 18.57 | 37.78 | 38.05 |
| Net Income From Continuing And Discontinued Operation | -154.81 | -146.96 | -223.86 | -311.35 |
| Total Operating Income As Reported | -161.26 | -165.53 | -261.63 | -349.40 |
| Diluted Average Shares | 53.93 | 58.37 | 75.04 | 0 |
| Basic Average Shares | 53.93 | 58.37 | 75.04 | 0 |
| Diluted NI Availto Com Stockholders | -154.81 | -146.96 | -223.86 | -311.35 |
| Net Income Including Noncontrolling Interests | -154.81 | -146.96 | -223.86 | -311.35 |
| Net Income Continuous Operations | -154.81 | -146.96 | -223.86 | -311.35 |
| Other Income Expense | 0 | 0 | -4.92 | -3.85 |
| Special Income Charges | 0 | 0 | -4.92 | -3.85 |
| Impairment Of Capital Assets | 0 | 0 | 4.92 | 3.85 |
| Net Non Operating Interest Income Expense | 6.45 | 18.57 | 37.78 | 38.05 |
| Interest Expense Non Operating | 0.18 | 0.20 | 0.25 | 0.37 |
| Interest Income Non Operating | 6.62 | 18.76 | 38.03 | 38.42 |
| General And Administrative Expense | 43.83 | 55.04 | 63.53 | 68.19 |
| Other Gand A | 43.83 | 55.04 | 63.53 | 68.19 |
| Operating Revenue | 46.83 | 78.59 | 47.07 | 39.21 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Kymera Therapeutics, Inc.this co. | KYMR | $6.7B | - | 4.20 | -19.7% | -17.38 |
| Apogee Therapeutics, Inc. | APGE | $7.3B | - | 6.21 | -28.3% | -17.34 |
| ImmunityBio, Inc. | IBRX | $7.2B | - | -14.06 | 70.3% | -32.25 |
| HealthEquity, Inc. | HQY | $6.9B | 33.12 | 3.29 | 10.2% | 15.69 |
| Arcellx, Inc. | ACLX | $6.7B | - |
| 16.56 |
| -56.9% |
| -25.69 |
| Spyre Therapeutics, Inc. | SYRE | $6.2B | - | 10.05 | 0.0% | - |
| Cogent Biosciences, Inc. | COGT | $6.1B | - | 10.56 | -51.7% | -15.73 |
| Terns Pharmaceuticals, Inc. | TERN | $6.1B | - | 5.91 | -9.6% | -46.26 |
| Hims & Hers Health, Inc. | HIMS | $6.1B | 51.63 | 11.06 | 23.7% | 37.26 |
| Peer Median | - | 42.37 | 8.13 | -4.8% | -17.34 | |